LEIDEN, Netherlands, April 5,
2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming"
or "the Company") (Euronext: PHARM) (Nasdaq: PHAR) announces that
the Company's 2023 Annual General Meeting of Shareholders (AGM)
will be held on Wednesday, May 17,
2023, at 14:00 CEST. The
Notice to Convene, Explanatory Notes, Voting information, meeting
documents and Form of Proxy can be found on the Company's website
under Investors/Shareholder Meetings.
The agenda of the AGM includes the proposal of the Board of
Directors, by way of a binding nomination, to re-appoint
Paul Sekhri for a period not to
exceed one year pending the current search for a new Chair of the
Board of Directors. In addition, the Board of Directors proposes,
by way of a binding nomination, to re-appoint Deborah Jorn, MBA, for a period of two
years.
The agenda further includes the proposals to re-appoint Deloitte
as the Company's external auditor for the financial years 2023 and
2024 and to amend the Company's articles of association to increase
the authorized capital.
The AGM will be held at the Corpus Congress Centre, Willem
Einthovenstraat 1, 2342 BH in Oegstgeest, the Netherlands.
About Pharming Group N.V.
Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is
a global biopharmaceutical company dedicated to transforming the
lives of patients with rare, debilitating, and life-threatening
diseases. Pharming is commercializing and developing an innovative
portfolio of protein replacement therapies and precision medicines,
including small molecules, biologics, and gene therapies that are
in early to late-stage development. Pharming is headquartered in
Leiden, Netherlands, and has
employees around the globe who serve patients in over 30 markets in
North America, Europe, the Middle
East, Africa, and
Asia-Pacific.
For more information, visit www.pharming.com and find us on
LinkedIn.
Inside Information
This press release relates to the disclosure of information that
qualifies, or may have qualified, as inside information within the
meaning of Article 7(1) of the EU Market Abuse Regulation.
For further public information, contact:
Pharming Group, Leiden, The
Netherlands
Michael Levitan, VP Investor Relations & Corporate
Communications
T: +1 (908) 705 1696
Heather Robertson, Investor
Relations & Corporate Communications Manager
E: investor@pharming.com
FTI Consulting, London,
UK
Victoria Foster
Mitchell/Alex Shaw/Amy
Byrne
T: +44 203 727 1000
LifeSpring Life Sciences Communication, Amsterdam, The Netherlands
Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl
Logo -
https://mma.prnewswire.com/media/2003587/3971133/Pharming_Group_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/pharming-group-convenes-the-annual-general-meeting-of-shareholders-2023-301789784.html
